Donald McDonnell: The use of high dose androgens as a treatment for Metastatic Prostate Cancer
Donald McDonnell, Professor at Department of Pharmacology and Cancer Biology at Duke University School of Medicine, reshared a post by Sandra Gordon on LinkedIn:
“A very nice article that describes the efforts by the Denmeade laboratory (JHU) and our group at Duke to mainstream the use of high dose androgens as a treatment for some patients with metastatic prostate cancer.
This was an idea proposed over 50 years ago but absent a mechanistic explanation as to how this modality worked it failed to develop.
This is now changing!”
Quoting Sandra Gordon‘s post:
“This emerging treatment for prostate cancer might just help men stay on hormone therapy longer.
My latest for Cancer Today.
Thank you to Dr. Donald McDonnell and Dr. Samuel Denmeade for your time and expertise!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023